Trastuzumab Rezetecan Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Exclusion Criteria

• •1. Breast cancer not histologically confirmed;
• •2. Known inherited or acquired bleeding and thrombotic tendencies;
• •3. Known allergy or contraindication to the study drug and its excipients;
• •4. Previously been treated with any anti-tumor therapy (chemotherapy, radiotherapy, molecular targeted therapy, endocrine therapy, etc.);
• •5. Concurrent receipt of any other form of anti-cancer therapy;
• •6. History of a second primary malignancy, except for adequately treated skin cancer;
• •7. Participation in other drug clinical trials within 4 weeks before enrollment;
• •8. Major surgical procedures unrelated to breast cancer within 4 weeks prior to the first drug administration, or not fully recovered from such procedures;
• •9. Presence of any active autoimmune disease or history of autoimmune disease with potential for recurrence;
• •10. Uncontrolled or significant cardiovascular and cerebrovascular diseases;
• •11. Subjects with known or suspected interstitial pneumonia;
• •12. Presence of active hepatitis B, hepatitis C, liver cirrhosis;
• •13. Pregnant or lactating female patients;
• •14. History of definite neurological or mental disorders, or any other conditions that the investigator believes make the patient unsuitable for participating in this study.